Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| GCRC#1083 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic state. This study is to determine whether metformin added to oral contraceptive therapy in adolescent women with PCOS improves metabolic state.The study will also test a lifestyle improvement program to reduce weight.
Polycystic Ovary Syndrome (PCOS) is a heterogeneous condition characterized by chronic anovulation and androgen excess that occurs in 4-8% of unselected adult women. Although signs and symptoms of the disorder typically appear at the time of puberty, diagnosis is often delayed until adulthood. At least 50% of adult women with PCOS are obese, resulting in a more severe clinical picture. Obesity among adolescents has been increasing in recent years, with overrepresentation of females who show evidence of hyperandrogenism and irregular periods, suggesting an association of obesity and PCOS at an early age. Recent data, however, have drawn attention to the long-term risks of PCOS, including diabetes and cardiovascular disease. Insulin resistance plays a critical role in the pathophysiology of PCOS and is thought to be the metabolic abnormality most closely linked to an increased risk of diabetes and heart disease. Traditional treatments with oral contraceptives are associated with reduction in serum androgens and improvements in menstrual cycles in adolescents with PCOS, however these have not been well-studied in obese adolescents. Oral contraceptives may worsen the dyslipidemia seen in obese women with PCOS and do not address the insulin resistance. Metformin, an insulin sensitizing agent, has been shown to improve metabolic features of PCOS, but combination therapy with oral contraceptives has never been studied in the obese adolescent with PCOS.
The major hypothesis of this proposal is that metformin will improve the metabolic profile of obese adolescent girls with PCOS treated with oral contraceptives. Additionally, a secondary hypothesis will be that compliance with a concurrent lifestyle modification program with be associated with the most significant improvements.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | metformin |
|
| 0 | Placebo Comparator | placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metformin | Drug | Metformin 500 mg. tabs 2 tabs BID for duration of study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reduction in Abdominal Fat as Measured by Waist Circumference. | Change in waist circumference measured in cms used as a measure of abdominal adiposity, pre minus post intervention | baseline and 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Weight Post Minus Pre Intervention. | Body mass index change in adolescents enrolled in lifestyle intervention program | baseline and 24 weeks |
| Total Testosterone Change | Change in total testosterone post minus pre intervention |
Not provided
Inclusion Criteria:Age 12-18 years; Menstrual irregularity; Overweight; Must be able to swallow capsules; At lease 6 months since onset of first menstrual cycle.
Exclusion Criteria:Diabetes; Kidney or Liver disease; Tobacco use; Depression or Bipolar Disease; Contraindication to exercise; Weight > 300 lbs.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kathleen Hoeger, MD | University of Rochester | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Rochester Medical Center | Rochester | New York | 14642 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Metformin | Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program |
| FG001 | Placebo | Subjects given a placebo in addition to oral contraceptive and lifestyle program |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Oral Contraceptive Pill | Drug | Yasmin, drospirenone and ethinyl estradiol 28 tablets 1 tab daily for duration of study |
|
|
| Lifestyle Management Program | Behavioral | Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study |
|
| Quality of Life Questionnaire | Behavioral | Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion |
|
| Oral Glucose Tolerance Test | Procedure | Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance. Performed twice during study, at baseline and conclusion |
|
| Blood work | Procedure | Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids. |
|
| Abdominal Ultra Sound | Procedure | transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume. Performed twice during study, at baseline and conclusion |
|
| Dual-energy x-ray absorptiometry (DEXA scan) | Procedure | Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion |
|
| placebo | Drug | placebo capsules, two capsules BID |
|
|
| baseline and 24 weeks |
| Change in Sex Hormone Binding Globulin (SHBG) | SHBG concentration post minus pre-intervention | baseline and 24 weeks |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Metformin | Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program |
| BG001 | Placebo | Subjects given a placebo in addition to oral contraceptive and lifestyle program |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Reduction in Abdominal Fat as Measured by Waist Circumference. | Change in waist circumference measured in cms used as a measure of abdominal adiposity, pre minus post intervention | Posted | Mean | Standard Deviation | cm | baseline and 24 weeks |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Change in Weight Post Minus Pre Intervention. | Body mass index change in adolescents enrolled in lifestyle intervention program | Posted | Mean | Standard Deviation | kg/m^2 | baseline and 24 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Total Testosterone Change | Change in total testosterone post minus pre intervention | Posted | Mean | Standard Deviation | ng/dL | baseline and 24 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Change in Sex Hormone Binding Globulin (SHBG) | SHBG concentration post minus pre-intervention | Posted | Mean | Standard Deviation | nmol/L | baseline and 24 weeks |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Metformin | Subjects given 2000mg of metformin in addition to oral contraceptive and a lifestyle program | 0 | 18 | 0 | 18 | ||
| EG001 | Placebo | Subjects given a placebo in addition to oral contraceptive and lifestyle program | 0 | 18 | 0 | 18 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Kathleen M. Hoeger, MD, MPH | University of Rochester Medical Center | 585-275-7891 | Kathy_Hoeger@urmc.rochester.edu |
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| D008599 | Menstruation Disturbances |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D008687 | Metformin |
| D003276 | Contraceptives, Oral |
| D005951 | Glucose Tolerance Test |
| D015502 | Absorptiometry, Photon |
| ID | Term |
|---|---|
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D003271 | Contraceptive Agents, Female |
| D003270 | Contraceptive Agents |
| D012102 | Reproductive Control Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045506 | Therapeutic Uses |
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008919 | Investigative Techniques |
| D011859 | Radiography |
| D003952 | Diagnostic Imaging |
| D003720 | Densitometry |
| D010783 | Photometry |
| D002623 | Chemistry Techniques, Analytical |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|